Abstract
Following publication of the original article [1], the authors identified a number of errors. In Result (P.3), Table 1 (P.4), Table 5 (P.9) and Supplementary Table 1, the correct unit for adiponectin was μg/mL. In Table 1 (P.4), the correct value for the post treatment body weight in dapagliflozin was 76.2±14.8. In Table 6 (P.10), the correct value for the pre treatment sd LDL/LDL-C in decreased LDL-C group was 0.38±0.10.
Cite
CITATION STYLE
Hayashi, T., Fukui, T., Nakanishi, N., Yamamoto, S., Tomoyasu, M., Osamura, A., … Hirano, T. (2017, November 13). Erratum: Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: Comparison with sitagliptin. [Cardiovasc Diabetol. 16, (2017) (8)] DOI: 10.1186/s12933-016-0491-5. Cardiovascular Diabetology. BioMed Central Ltd. https://doi.org/10.1186/s12933-017-0608-5
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
